This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.
Key Features
* Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease
* Provides the first definitive overview of adenosine antagonists and their role in the treatment of Parkinson's disease
* Presents a new mechanism of action of adenosine A2A receptor antagonists in motor function
Proposes a hypothesis of adenosine A2A receptor function in the striatum
* Comprehensive overview of adenosine, its receptor subtypes, their antagonists/agonists from biochemistry, molecular biology, medicinal chemistry, physiology, pharmacology, and neurochemistry viewpoints
Key Features
* Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease
* Provides the first definitive overview of adenosine antagonists and their role in the treatment of Parkinson's disease
* Presents a new mechanism of action of adenosine A2A receptor antagonists in motor function
Proposes a hypothesis of adenosine A2A receptor function in the striatum
* Comprehensive overview of adenosine, its receptor subtypes, their antagonists/agonists from biochemistry, molecular biology, medicinal chemistry, physiology, pharmacology, and neurochemistry viewpoints
